Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2693-2700

  Wu, Qing Yun ^a,b   Guo, Hua Yan ^a   Li, Feng ^a   Li, Zhen Yu ^a   Zeng, Ling Yu ^a   Xu, Kai Lin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Laboratory of Transplantation and Immunology   (China)

Author keywords

B cell acute lymphoblastic leukemia; Conformational change; Constitutive activation; Drug target; Janus kinase 2; Mutation

Indexed keywords

INTERLEUKIN 3; JANUS KINASE 2; STAT5 PROTEIN;

ARTICLE; B CELL LEUKEMIA; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN INTERACTION; SPECTROSCOPY;

CELL LINE, TUMOR; CELL PROLIFERATION; CODON; ENZYME ACTIVATION; ERYTHROPOIETIN; HUMANS; JANUS KINASE 2; MODELS, MOLECULAR; MUTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84887219711     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.781171     Document Type: Article

References (30)

1. Broxmeyer HE . Getting to know JAK . Blood 2011 ; 118 : 6235-6237 .
2. Rawlings JS, Rosler KM, Harrison DA . The JAK/STAT signaling pathway . J Cell Sci 2004 ; 117 : 1281-1283 .
3. Bercovich D, Ganmore I, Scott LM, et al . Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down' s syndrome . Lancet 2008 ; 372 : 1484-1492 .
4. Mullighan CG, Zhang J, Harvey RC, et al . JAK mutations in highrisk childhood acute lymphoblastic leukemia . Proc Natl Acad Sci USA 2009 ; 106 : 9414-9418 .
5. Mullighan CG . New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice . Clin Cancer Res 2011; 17: 396-400.
6. Tasian SK, Doral MY, Borowitz MJ, et al . Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia . Blood 2012; 120: 833-842.
7. Yoda A, Y oda Y, C hiaretti S, et a l. F unctional screening identifi es CRLF2 in precursor B-cell acute lymphoblastic leukemia . Proc Natl Acad Sci USA 2010 ; 107 : 252-257 .
8. Kearney L, G onzalez De Castro D, Y eung J, et a l. S pecifi c JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia . Blood 2009; 113: 646-648.
9. Harvey R C, M ullighan C G, W ang X, et a l. I dentifi cation of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profi ling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome . Blood 2010 ; 116 : 4874-4884 .
10. Roll J D, R euther G W. C RLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis . Cancer Res 2010; 70: 7347-7352.
11. Lee TS, Ma W, Zhang X, et al . Structural eff ects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations . BMC Struct Biol 2009 ; 9 : 58-62 .
12. Giordanetto F, Kroemer RT . Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7 . Protein Eng 2002; 15: 727-737.
13. Morris GM, Huey R, Lindstrom W, et al . AutoDock4 and AutoDock Tools4: automated docking with selective receptor fl exibility. J Comput Chem 2009 ; 30 : 2785-2791 .
14. Ungureanu D, Wu J, Pekkala T, et al . The pseudokinase domain of JAK2 is a dual-specifi city protein kinase that negatively regulates cytokine signaling . Nat Struct Mol Biol 2011; 18: 971-976.
15. Lindauer K, Loerting T, Liedl KR, et al . Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation . Protein Eng 2001 ; 14 : 27-37 .
16. Phillips JC, Braun R, Wang W, et al . Scalable molecular dynamics with NAMD . J Comput Chem 2005; 26: 1781-1802.
17. Zhang L, Hermans J . Hydrophilicity of cavities in proteins . Proteins 1996 ; 24 : 433-438 .
18. Brooks BR, Bruccoleri RE, Olafson BD, et al . CHARMM: a program for macromolecular energy, minimization, and dynamics calculations . J Comput Chem 1983; 4: 187-217.
19. Wu QY, Li F, Guo HY, et al . Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation . Arch Biochem Biophys 2012 ; 528 : 57-66 .
20. Zhao L, Ma Y, Seemann J, et al . A regulating role of the JAK2 FERM domain in hyperactivation of JAK2 (V617F) . Biochem J 2010 ; 426 : 91-98 .
21. Teff eri A . J AK inhibitors for myeloproliferative neoplasms: clarifying facts from myths . Blood 2012; 119: 2721-2730.
22. Seubert N, Royer Y, Staerk J, et al . Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimmer . Mol Cell 2003 ; 12 : 1239-1250 .
23. Dumoutier L, Van Roost E, Colau D, et al . Human interleukin-10-related T cell-derived inducible factor:molecular cloning and functional characterization as a hepatocyte-stimulating factor . Proc Natl Acad Sci USA 2000 ; 97 : 10144-10149 .
24. Ihle J N, G illiland D G. J ak2: normal function and role in hematopoietic disorders . Curr Opin Genet Dev 2007 ; 17 : 8-14 .
25. Lafave LM, Levine RL . JAK2 the future: therapeutic strategies for JAK-dependent malignancies . Trends Pharmacol Sci 2012; 33: 574-582.
26. Green MR, Monti S, Rodig SJ, et al . Integrative analysis reveals selective 9p24.1 amplifi cation, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma . Blood 2010 ; 116 : 3268-3277 .
27. Rui L, Emre NC, Kruhlak MJ, et al . Cooperative epigenetic modulation by cancer amplicon genes . Cancer Cell 2010; 18: 590-605.
28. Quint á s-Cardama A, Vaddi K, Liu P, et al . Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms . Blood 2010 ; 115 : 3109-3117 .
29. Ostojic A, Vrhovac R, Verstovsek S . Ruxolitinib for the treatment of myelofi brosis: its clinical potential . Ther Clin Risk Manag 2012 ; 8 : 95-103 .
30. Maude SL, Tasian SK, Vincent T, et al . Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia (ALL) . Blood 2012 ; 12 : 3510-3518 .